Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Non Operating Income (2022 - 2025)

Historic Non Operating Income for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$12.5 million.

  • BioXcel Therapeutics' Non Operating Income fell 36045.26% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 11196.49%. This contributed to the annual value of $20.2 million for FY2024, which is 502005.08% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Non Operating Income of -$12.5 million as of Q3 2025, which was down 36045.26% from $657000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' Non Operating Income's 5-year high stood at $12.0 million during Q2 2024, with a 5-year trough of -$12.5 million in Q3 2025.
  • For the 4-year period, BioXcel Therapeutics' Non Operating Income averaged around $1.1 million, with its median value being $108000.0 (2023).
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 9644000.0% in 2024, then crashed by 36045.26% in 2025.
  • BioXcel Therapeutics' Non Operating Income (Quarter) stood at -$480000.0 in 2022, then surged by 122.5% to $108000.0 in 2023, then skyrocketed by 2953.7% to $3.3 million in 2024, then plummeted by 480.41% to -$12.5 million in 2025.
  • Its Non Operating Income was -$12.5 million in Q3 2025, compared to $657000.0 in Q2 2025 and $6.6 million in Q1 2025.